查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836852

早洩治療市場（按治療類型、最終用戶和劑型分類）—全球預測 2025-2032

Premature Ejaculation Treatment Market by Treatment Type, End User, Dosage Form - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，早洩治療市場規模將成長至 83.3 億美元，複合年成長率為 10.09%。

主要市場統計數據
基準年2024年 38.6億美元
預計2025年 42.4億美元
預測年份：2032年 83.3億美元
複合年成長率（%） 10.09%

策略性地介紹早洩治療前景，概述臨床挑戰、病人歷程、不斷發展的治療模式和未滿足的需求

早洩治療是一個複雜的交叉領域，涉及臨床科學、患者行為和商業性創新。患者的症狀和合併症各不相同，需要個別化評估和治療順序。臨床醫生在選擇介入措施（從行為介入和設備到全身和局部藥物治療）時，必須權衡療效、耐受性、起效時間、易用性和患者偏好。不斷變化的監管環境、患者權益倡導以及對生活品質日益成長的關注也進一步影響著這一領域。

隨著相關人員尋求將產品開發與臨床需求結合，客觀結果指標和病患報告結果的角色日益重要。因此，藥物開發越來越注重標準化終點的可重複效應大小以及患者滿意度的顯著提升。同時，護理途徑也在不斷調整，以整合遠端醫療、遠距監控和家庭治療，從而提高依從性並減少因污名化而導致的就醫障礙。這些動態正在為差異化治療方法創造臨床和商業性機會，這些方法在現實環境中具有顯著的益處。

最後，臨床醫生教育、支付方參與和患者認知之間的相互作用決定了治療的接受度和持續使用。制定策略性計劃，重點關注臨床醫生教育、最佳化患者諮詢並展示不同治療方法的比較優勢，對於將臨床進展轉化為可衡量的醫療改善至關重要。

治療方式的轉變、數位療法的普及、監管變化和商業性動態正在重新定義臨床護理和行業重點

近年來，早洩的概念、診斷和治療方法發生了重大變化。數位療法和行為健康服務的進步擴大了實證介入措施的可及性，而這些介入措施先前僅限於面對面治療。同時，標靶環和先進的振動刺激平台等設備設計的創新，正在拓展非藥物治療方案，並促成更多以患者為中心的自我管理策略。這些變化與局部用藥配方的改良相輔相成，這些配方經過最佳化，可快速起效，耐受性也更佳。

監管格局正朝著更清晰的方向發展，以支持將行為介入與藥物或基於設備的療法相結合的聯合療法。這些監管變革正鼓勵臨床開發人員追求整合治療模式，並優先考慮以患者為中心的穩健終點。同時，商業性環境也正在回應日益成長的便利、謹慎且可報銷解決方案的需求，促使製造商探索新的分銷管道和支援服務，以提高患者初始用藥率和依從性。

綜上所述，這些轉變正在創造一個更多樣化的治療生態系統。利害關係人若能適應這種多層面的醫療框架——強調便利性、顯著的患者獲益和可擴展的交付——將能夠更好地滿足臨床需求，並開闢新的應用途徑。

評估 2025 年美國關稅環境及其對治療和醫療設備相關人員的營運、供應鏈和商業性影響

2025年美國關稅的實施，為參與早洩藥物和器械生產、進口和分銷的相關人員帶來了新的經濟變數。依賴跨國採購活性藥物成分、器械組件或成品的供應鏈受到了越來越嚴格的審查，促使其重新評估籌資策略。製造商和供應商對此做出了回應，評估替代採購、本地化生產以及談判供應協議，並更加重視關稅風險和總到岸成本。

關稅格局也影響定價策略和產品發布順序，一些公司選擇在地化生產並優先考慮策略庫存，以緩解短期成本波動。此外，契約製造製造商和零件供應商擴大提供配套服務和基於價值的安排，以抵消關稅相關成本的增加。從商業性角度來看，付款人和採購機構越來越關注成本透明度和可預測的定價模型，這可能會影響處方決策和合約條款。

重要的是，這些發展正在加速圍繞在岸外包、策略供應商夥伴關係以及長期供應韌性的討論。因此，投資於靈活生產能力、雙重採購策略和主動定價模式的製造商將能夠更好地應對成本壓力，同時保持醫療服務的可及性和連續性。

跨治療類型、最終用戶管道和劑型的詳細細分洞察，為產品開發和商業化策略提供資訊

細分分析揭示了按治療類型、最終用戶和劑型分類的不同產品開發、商業化和臨床採用途徑。基於治療類型的治療方法包括非藥物干預、藥物全身性用藥和局部治療。非藥物策略進一步分為行為療法和設備。行為療法細分為感覺聚焦和啟動停止療法等方法，而設備則涵蓋收縮環溶液和振動刺激等方式。藥物全身療法包括磷酸二酯酶抑制劑和選擇性血清素再回收抑制劑等類別。前者包括Sildenafil和他達拉非等藥物，而後者包括專用藥物如達泊西汀和仿單標示外SSRI，如Fluoxetine、Lidocaine和舍曲林。局部治療的特點是使用局部麻醉劑，常見的有Lidocaine乳膏、利多卡因-Prilocaine噴霧劑和Prilocaine乳膏。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 將數位療法與智慧型手機應用程式結合，實現早洩的個人化管理
  • 新興市場仿單標示外抗憂鬱症和局部麻醉劑的採用率不斷提高
  • 擴展遠端醫療平台，實現早洩照護的保密虛擬諮詢
  • 行為療法和骨盆底訓練等非藥物干預措施的研究激增
  • 開發新型、速效、選擇性血清素再回收抑制劑，用於按需治療 PE
  • 製藥公司擴大與數位健康Start-Ups的合作，提供綜合 PE 解決方案
  • 在 PE 治療中，越來越多的患者偏好採用口服和局部藥物相結合的聯合治療
  • 監管進展簡化了針對 PE 的創新訊號通路調節劑的核准途徑
  • 打入市場策略著重於在亞太地區 PE 治療市場採用具有成本效益的學名藥和生物相似藥
  • 消費者遠端醫療平台對早洩照護的可近性和依從性的影響。

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章早洩治療市場（依治療類型）

  • 非藥物治療
    • 行為療法
      • 感官聚焦
      • 啟停技術
    • 裝置
      • 夾緊環
      • 震動刺激
  • 藥理學系統
    • 磷酸二酯酶抑制劑
      • Sildenafil
      • 他達拉非
    • 選擇性血清素再回收抑制劑
      • 達泊西汀
      • 非標籤藥物用藥
      • Fluoxetine
      • 帕羅西汀
      • 舍曲林
  • 話題
    • 局部麻醉劑
      • Lidocaine乳膏
      • LidocainePrilocaine噴霧
      • Prilocaine乳膏

第9章早洩治療市場（依最終用戶）

  • 診所
  • 居家護理
  • 醫院

第 10 章早洩治療市場（以劑型）

  • 奶油
  • 噴
  • 藥片

第11章早洩治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章早洩治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 早洩治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Menarini Group
    • Teva Pharmaceuticals Industries Ltd.
    • Cipla Limited
    • Lupin Limited
    • Sun Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • Panacea Biotec Ltd.
    • Endo International plc
    • Reckitt Benckiser Group plc
    • Bayer AG
Product Code: MRR-030EE48515EB

The Premature Ejaculation Treatment Market is projected to grow by USD 8.33 billion at a CAGR of 10.09% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.86 billion
Estimated Year [2025] USD 4.24 billion
Forecast Year [2032] USD 8.33 billion
CAGR (%) 10.09%

Strategic introduction to premature ejaculation treatment landscape, outlining clinical challenges, patient journeys, evolving care paradigms and unmet needs

The treatment of premature ejaculation occupies a complex intersection of clinical science, patient behavior, and commercial innovation. Patients present with heterogeneous symptom profiles and comorbidities that require individualized assessment and therapeutic sequencing. Clinicians balance efficacy, tolerability, onset of action, ease of use, and patient preferences when selecting interventions, which range from behavioral interventions and devices to systemic and topical pharmacotherapies. This landscape is further influenced by evolving regulatory expectations, patient advocacy, and increasing attention to quality of life outcomes.

As stakeholders seek to align product development with clinical need, the role of objective outcome measures and patient-reported outcomes has grown in prominence. Consequently, therapeutic development increasingly emphasizes reproducible effect size on standardized endpoints and meaningful improvements in patient satisfaction. Concurrently, care pathways are adapting to integrate telehealth, remote monitoring, and home-based therapies that support adherence and reduce stigma-related barriers to seeking care. These dynamics create both clinical and commercial opportunities for differentiated therapeutic approaches that deliver demonstrable benefits in real-world settings.

Finally, the interplay between clinician education, payer engagement, and patient awareness determines uptake and sustained use of treatments. Strategic programs that address clinician guidance, optimize patient counseling, and demonstrate comparative advantages of treatment modalities will be critical to translating clinical advances into measurable improvements in care.

Transformations across treatment modalities, digital therapeutics uptake, regulatory shifts and commercial dynamics redefining clinical care and sector focus

Recent years have witnessed substantive shifts that are reshaping how premature ejaculation is conceptualized, diagnosed, and treated. Advances in digital therapeutics and behavioral health delivery have expanded access to evidence-based interventions that were previously constrained to in-person therapy. At the same time, innovations in device design, such as targeted constrictive rings and refined vibratory stimulation platforms, are broadening nonpharmacological options and enabling more patient-centric self-management strategies. These changes are complemented by refinements in topical formulations optimized for rapid onset and predictable tolerability profiles.

Regulatory landscapes are moving toward clearer pathways for combination approaches that pair behavioral interventions with pharmacologic or device-based therapies. This regulatory evolution has encouraged clinical developers to pursue integrated treatment models and to prioritize robust, patient-centered endpoints. In parallel, the commercial environment is responding to greater demand for convenient, discreet, and reimbursable solutions, prompting manufacturers to explore novel distribution channels and support services that improve initiation and adherence.

Taken together, these shifts are creating a more diversified therapeutic ecosystem. Stakeholders that adapt to a multifaceted care framework-one that values convenience, demonstrable patient benefit, and scalable delivery-will be better positioned to meet clinical needs while unlocking new adoption pathways.

Assessment of the 2025 United States tariff environment and its operational, supply chain, and commercial implications for therapeutic and device stakeholders

The introduction of tariffs by the United States in 2025 has introduced a new economic variable for stakeholders involved in the manufacture, importation, and distribution of therapies and devices for premature ejaculation. Supply chains that rely on cross-border sourcing of active pharmaceutical ingredients, device components, or finished goods have experienced increased scrutiny, prompting a reassessment of procurement strategies. Manufacturers and suppliers have responded by evaluating alternative sourcing, regionalizing production, and negotiating supply contracts with greater emphasis on tariff exposure and total landed cost.

This tariff landscape has also affected pricing strategies and launch sequencing, with some organizations electing to localize manufacturing or prioritize strategic inventory to mitigate short-term cost volatility. In addition, contract manufacturers and component suppliers have become more proactive in offering bundled services and value-based arrangements that can offset incremental tariff-related expenses. From a commercial perspective, payers and procurement entities are increasingly focused on cost transparency and predictable pricing models, which can influence formulary decisions and contracting terms.

Importantly, these developments have accelerated conversations around onshoring, strategic supplier partnerships, and long-term supply resilience. As a result, manufacturers that invest in flexible production capacity, dual-sourcing strategies, and proactive tariff modeling will be better equipped to manage cost pressures while preserving access and continuity of care.

In-depth segmentation insights connecting treatment types, end-user channels, and dosage forms to inform product development and commercialization strategies

Segmentation analysis reveals nuanced pathways for product development, commercialization, and clinical adoption, each driven by distinct treatment types, end users, and dosage forms. Based on treatment type, therapeutic approaches encompass nonpharmacological interventions, pharmacological systemic agents, and topical treatments. Nonpharmacological strategies are further differentiated into behavioral therapy and devices, with behavioral therapy subdivided into methods such as sensate focus and start-stop techniques and devices covering modalities like constrictive ring solutions and vibratory stimulation. Pharmacological systemic options include classes such as phosphodiesterase inhibitors and selective serotonin reuptake inhibitors, where the former comprises agents like sildenafil and tadalafil and the latter includes both dedicated agents such as dapoxetine and off-label SSRIs that involve fluoxetine, paroxetine, and sertraline. Topical treatments are characterized by local anesthetics, with common formulations including lidocaine cream, lidocaine-prilocaine spray, and prilocaine cream.

Based on end user, delivery and adoption pathways differ across clinics, home care settings, and hospitals, each presenting unique adoption drivers related to clinician oversight, privacy considerations, and reimbursement. Based on dosage form, patient preference and adherence are influenced by creams, sprays, and tablets, with each form presenting trade-offs in onset, ease of use, and perceived intrusiveness. Taken together, these segmentation dimensions highlight the importance of aligning product design, clinical evidence generation, and patient support programs to the specific needs and behaviors of the intended end users and preferred dosage forms. By mapping clinical benefit profiles to these segment attributes, developers and commercial teams can better prioritize development portfolios and tailor go-to-market strategies that resonate with both prescribers and users.

Key regional dynamics and differentiated strategic approaches required for successful adoption across Americas, Europe Middle East & Africa and Asia-Pacific

Regional dynamics shape regulatory pathways, payer behavior, and clinical practice in distinct ways across the Americas, Europe Middle East & Africa, and Asia-Pacific regions. In the Americas, regulatory frameworks and payer interactions emphasize comparative effectiveness and reimbursement evidence, while health care delivery models favor a mix of clinic-based and home care approaches that accommodate telehealth integration and private payer engagement. In Europe Middle East & Africa, diverse regulatory regimes and heterogeneous health systems necessitate regionally tailored evidence packages and local stakeholder engagement, with certain markets placing heightened emphasis on real-world effectiveness and cost-effectiveness assessments. In the Asia-Pacific region, rapid digital adoption, varying reimbursement landscapes, and a strong focus on localized clinical validation make market entry strategies reliant on partnerships, local regulatory expertise, and culturally adapted patient engagement programs.

Cross-regionally, supply chain considerations, regulatory timelines, and clinician practice patterns influence launch sequencing and resource allocation. The interplay between regional reimbursement policies and patient acceptance of topical versus systemic therapies informs how companies prioritize clinical trials and post-market evidence generation. Therefore, a geographically nuanced approach that aligns evidence generation, regulatory strategy, and commercial operations to regional expectations is essential for achieving sustained adoption and clinical integration.

Company-level strategic trends highlighting product differentiation, partnership models, and evidence generation priorities across the competitive landscape

Competitive activity is increasingly characterized by converging approaches across pharmacologic, device, and behavioral domains, with companies pursuing differentiated formulations, delivery mechanisms, and service-oriented care models. Late-stage developers and established manufacturers are investing in faster-onset topical agents and combination strategies that pair pharmacologic effects with behavioral support, while device innovators focus on usability, discreet form factors, and evidence of durable benefit. Strategic alliances between pharmaceutical developers and digital health providers are also emerging, aiming to bundle therapeutics with adherence and behavioral coaching to enhance outcomes.

In parallel, contract manufacturing and component suppliers are evolving to offer integrated solutions that reduce time to market and mitigate supply chain risks. Clinical development programs increasingly emphasize standardized outcome measures and pragmatic trial designs that capture real-world effectiveness and patient-reported outcomes. Additionally, commercial organizations are refining payer engagement and value demonstration strategies to address reimbursement hurdles, focusing on outcomes that matter to both clinicians and patients.

Collectively, these company-level trends suggest that competitive advantage will accrue to organizations that combine robust clinical evidence, patient-centric delivery models, and supply chain resilience. Firms that can articulate clear value propositions to payers, clinicians, and end users while maintaining flexible operational capabilities will be better positioned to navigate an evolving landscape.

Actionable recommendations for leaders to integrate clinical differentiation, supply chain resilience, and patient-centric commercialization for long-term success

Industry leaders should adopt a multi-pronged strategy that integrates clinical differentiation, supply chain resilience, and patient-centric commercialization. First, prioritizing clinical programs that demonstrate fast onset, favorable tolerability, and meaningful patient-reported outcomes will increase the clinical credibility of new therapies. Second, implementing diversified sourcing strategies and exploring nearshoring or dual-sourcing arrangements can mitigate tariff and supply chain risks while preserving cost competitiveness.

Third, developing integrated care propositions that combine pharmacologic or device therapies with digital behavioral support can enhance adherence and real-world effectiveness. Fourth, engaging early with regulators and payers to define evidence requirements and reimbursement pathways will reduce time to adoption and improve pricing negotiations. Fifth, tailoring market entry and commercialization plans to regional nuances-taking into account regulatory expectations, cultural preferences, and health system structures-will boost local acceptance and uptake. Finally, investing in clinician education and patient support programs that address stigma, set realistic expectations, and simplify use will be essential to drive longer-term adoption.

Collectively, these recommendations encourage organizations to balance innovation with operational rigor and stakeholder alignment, enabling sustainable growth and improved patient outcomes.

Robust mixed-methods research methodology combining primary stakeholder interviews, secondary evidence synthesis and supply chain scenario analysis

The research underpinning this executive summary employed a mixed-methods approach combining primary qualitative interviews, secondary literature synthesis, regulatory document review, and supply chain analysis. Primary research included structured interviews with clinicians, clinical trial investigators, payers, and commercial leaders to capture experiential insights on treatment selection, reimbursement barriers, and patient adherence patterns. Secondary sources encompassed peer-reviewed clinical literature, regulatory guidance documents, clinical trial registries, and patents to validate therapeutic mechanisms, safety signals, and evidence gaps.

Analytical frameworks integrated segmentation mapping, scenario analysis for tariff and supply chain impacts, and comparative assessment of therapeutic modalities across clinical and operational dimensions. Throughout the process, triangulation of data sources ensured that conclusions reflected a balanced synthesis of clinical evidence, stakeholder perspectives, and operational considerations. Limitations of the research-such as evolving regulatory positions and emerging clinical data-were addressed through sensitivity checks and consultation with subject-matter experts. The methodology prioritizes transparency, reproducibility, and alignment with best practices for healthcare market research, thereby providing a defensible basis for the insights and recommendations presented.

Concise conclusion synthesizing clinical, operational, and commercial imperatives to advance care and improve outcomes in premature ejaculation treatment

In summary, the therapeutic landscape for premature ejaculation is in the midst of meaningful evolution, characterized by advances in topical agents, device innovation, digital behavioral supports, and shifting regulatory and commercial dynamics. These trends underscore the importance of an integrated approach that couples robust clinical evidence with patient-centered delivery and resilient operations. Stakeholders that proactively address tariff-induced supply chain vulnerabilities, align product design to end-user preferences across clinics, home care, and hospitals, and demonstrate clear value to payers will be better positioned to capture clinical adoption and sustain commercial performance.

Looking forward, collaborations that bridge pharmacologic, device, and behavioral domains offer the potential to deliver more comprehensive and effective care pathways. Moreover, regionally nuanced strategies that account for differences across the Americas, Europe Middle East & Africa, and Asia-Pacific will be critical to successful implementation. Ultimately, the organizations that combine clinical credibility, operational agility, and stakeholder engagement will lead future advances in care and patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of digital therapeutics and smartphone apps for personalized premature ejaculation management
  • 5.2. Rising adoption of off-label antidepressants and topical anesthetics in emerging markets
  • 5.3. Expansion of telehealth platforms enabling discreet virtual consultations for premature ejaculation care
  • 5.4. Surge in research on non-pharmacological interventions such as behavioral therapy and pelvic floor training
  • 5.5. Development of novel fast-acting selective serotonin reuptake inhibitors designed for on-demand usage in PE treatment
  • 5.6. Growing collaborations between pharmaceutical companies and digital health startups to deliver integrated PE solutions
  • 5.7. Increasing patient preference for combination therapies integrating oral and topical formulations in PE management
  • 5.8. Regulatory advancements streamlining approval pathways for innovative signal transduction pathway modifiers targeting PE
  • 5.9. Market entry strategies focusing on cost-effective generics and biosimilars adoption in Asia-Pacific PE treatment market
  • 5.10. Impact of direct-to-consumer telemedicine platforms on accessibility and adherence in premature ejaculation care

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Premature Ejaculation Treatment Market, by Treatment Type

  • 8.1. Non Pharmacological
    • 8.1.1. Behavioral Therapy
      • 8.1.1.1. Sensate Focus
      • 8.1.1.2. Start Stop Technique
    • 8.1.2. Devices
      • 8.1.2.1. Constrictive Ring
      • 8.1.2.2. Vibratory Stimulation
  • 8.2. Pharmacological Systemic
    • 8.2.1. Phosphodiesterase Inhibitors
      • 8.2.1.1. Sildenafil
      • 8.2.1.2. Tadalafil
    • 8.2.2. Selective Serotonin Reuptake Inhibitors
      • 8.2.2.1. Dapoxetine
      • 8.2.2.2. Off Label Ssris
      • 8.2.2.2.1. Fluoxetine
      • 8.2.2.2.2. Paroxetine
      • 8.2.2.2.3. Sertraline
  • 8.3. Topical
    • 8.3.1. Local Anesthetics
      • 8.3.1.1. Lidocaine Cream
      • 8.3.1.2. Lidocaine Prilocaine Spray
      • 8.3.1.3. Prilocaine Cream

9. Premature Ejaculation Treatment Market, by End User

  • 9.1. Clinics
  • 9.2. Home Care
  • 9.3. Hospitals

10. Premature Ejaculation Treatment Market, by Dosage Form

  • 10.1. Creams
  • 10.2. Sprays
  • 10.3. Tablets

11. Premature Ejaculation Treatment Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Premature Ejaculation Treatment Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Premature Ejaculation Treatment Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Menarini Group
    • 14.3.2. Teva Pharmaceuticals Industries Ltd.
    • 14.3.3. Cipla Limited
    • 14.3.4. Lupin Limited
    • 14.3.5. Sun Pharmaceutical Industries Ltd.
    • 14.3.6. Sandoz International GmbH
    • 14.3.7. Panacea Biotec Ltd.
    • 14.3.8. Endo International plc
    • 14.3.9. Reckitt Benckiser Group plc
    • 14.3.10. Bayer AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. PREMATURE EJACULATION TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. PREMATURE EJACULATION TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PREMATURE EJACULATION TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SENSATE FOCUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SENSATE FOCUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SENSATE FOCUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SENSATE FOCUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SENSATE FOCUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SENSATE FOCUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY START STOP TECHNIQUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY START STOP TECHNIQUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY START STOP TECHNIQUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY START STOP TECHNIQUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY START STOP TECHNIQUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY START STOP TECHNIQUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CONSTRICTIVE RING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CONSTRICTIVE RING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CONSTRICTIVE RING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CONSTRICTIVE RING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CONSTRICTIVE RING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CONSTRICTIVE RING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY VIBRATORY STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY VIBRATORY STIMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY VIBRATORY STIMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY VIBRATORY STIMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY VIBRATORY STIMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY VIBRATORY STIMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SILDENAFIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SILDENAFIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SILDENAFIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SILDENAFIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SILDENAFIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SILDENAFIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TADALAFIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TADALAFIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TADALAFIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TADALAFIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TADALAFIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TADALAFIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DAPOXETINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DAPOXETINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DAPOXETINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DAPOXETINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DAPOXETINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DAPOXETINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY FLUOXETINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY FLUOXETINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY FLUOXETINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY FLUOXETINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY FLUOXETINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PAROXETINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PAROXETINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PAROXETINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PAROXETINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PAROXETINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SERTRALINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SERTRALINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SERTRALINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SERTRALINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SERTRALINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIDOCAINE CREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIDOCAINE CREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIDOCAINE CREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIDOCAINE CREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIDOCAINE CREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIDOCAINE CREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIDOCAINE PRILOCAINE SPRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIDOCAINE PRILOCAINE SPRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIDOCAINE PRILOCAINE SPRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIDOCAINE PRILOCAINE SPRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIDOCAINE PRILOCAINE SPRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIDOCAINE PRILOCAINE SPRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PRILOCAINE CREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PRILOCAINE CREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PRILOCAINE CREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PRILOCAINE CREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PRILOCAINE CREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PRILOCAINE CREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SPRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SPRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SPRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL SYSTEMIC, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFF LABEL SSRIS, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-20